Presentation Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US May 11, 2018 REGISTER for free or LOG IN to view this content Structural Heart Aortic Valve Factoid TAVR SAVR Up Next Presentation Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016 May 21, 2018 More slides + Presentation EuroPCR 2018 ORBITA: A Physiology-stratified Analysis of the Impact of FFR and iFR on Efficacy of Coronary Angioplasty in Stable Coronary Artery Disease Presenter: Rasha Al-Lamee May 22, 2018 Presentation EuroPCR 2018 PCI Statement on PCI Treatment for Chronic Coronary Syndrome Presenter: Michael Haude May 22, 2018 We Recommend
Presentation Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016 May 21, 2018
Presentation EuroPCR 2018 ORBITA: A Physiology-stratified Analysis of the Impact of FFR and iFR on Efficacy of Coronary Angioplasty in Stable Coronary Artery Disease Presenter: Rasha Al-Lamee May 22, 2018
Presentation EuroPCR 2018 PCI Statement on PCI Treatment for Chronic Coronary Syndrome Presenter: Michael Haude May 22, 2018